{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:43:20Z","timestamp":1777556600211,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.clml.2021.03.002","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T03:01:36Z","timestamp":1616209296000},"page":"431-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma: A Meta-analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Phuong Nhat","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngoc T.B.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Truong P.X.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam N.M","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doan Van","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsey D.","family":"Deel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis A.","family":"Hassell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huy Gia","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.03.002_bib0001","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.03.002_bib0002","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MD.0b013e3181573059","article-title":"Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients","volume":"86","author":"Lachenal","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clml.2021.03.002_bib0003","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.03.002_bib0004","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.03.002_bib0005","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.002_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM197501022920101","article-title":"Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease","volume":"292","author":"Lukes","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.03.002_bib0007","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0002-9343(75)90466-0","article-title":"Angio-immunoblastic lymphadenopathy: diagnosis and clinical course","volume":"59","author":"Frizzera","year":"1975","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2021.03.002_bib0008","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.002_bib0009","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V99.2.627","article-title":"Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10","volume":"99","author":"Attygalle","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.002_bib0010","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma","volume":"30","author":"Dorfman","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2021.03.002_bib0011","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2005-03-1083","article-title":"Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?","volume":"106","author":"Grogg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.002_bib0012","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3324\/haematol.10864","article-title":"Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma","volume":"92","author":"Roncador","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.03.002_bib0013","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.03.002_bib0014","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2021.03.002_bib0015","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2021.03.002_bib0016","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2021.03.002_bib0017","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.002_bib0018","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V122.21.815.815","article-title":"Somatic G17V Rhoa mutation specifies angioimmunoblastic T-cell lymphoma","volume":"122","author":"Sakata-Yanagimoto","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.002_bib0019","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41379-019-0254-4","article-title":"The pathological features of angioimmunoblastic T-cell lymphomas with IDH2(R172) mutations.","volume":"32","author":"Steinhilber","year":"2019","journal-title":"Modern Pathol"},{"key":"10.1016\/j.clml.2021.03.002_bib0020","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1038\/bcj.2016.122","article-title":"Identification of cell-type-specific mutations in nodal T-cell lymphomas","volume":"7","author":"Nguyen","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.03.002_bib0021","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/cas.13393","article-title":"Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma","volume":"109","author":"Fukumoto","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2021.03.002_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.clml.2021.03.002_bib0023","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.clml.2021.03.002_bib0024","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2021.03.002_bib0025","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bmj.39343.408449.80","article-title":"Uncertainty in heterogeneity estimates in meta-analyses","volume":"335","author":"Evangelou","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2021.03.002_bib0026","series-title":"User manual for meta-essentials: Workbooks for meta-analyses","author":"Van Rhee","year":"2015"},{"key":"10.1016\/j.clml.2021.03.002_bib0027","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/10428194.2019.1702179","article-title":"Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for RHOA G17V mutated subtype","volume":"61","author":"Hsu","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.03.002_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2019.104294","article-title":"RHOA G17V mutation in angioimmunoblastic T-cell lymphoma: a potential biomarker for cytological assessment","volume":"110","author":"Lee","year":"2019","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.clml.2021.03.002_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2020.1768382","article-title":"Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the RHOA(G17V) and IDH2(R172) hot-spot mutations in plasma cell-free DNA as liquid biopsy for the diagnosis of angioimmunoblastic T-cell lymphoma","volume":"61","author":"Hayashida","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.03.002_bib0030","doi-asserted-by":"crossref","first-page":"16124","DOI":"10.18632\/oncotarget.24592","article-title":"Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features","volume":"9","author":"Manso","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2021.03.002_bib0031","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.03.002_bib0032","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/PAI.0000000000000644","article-title":"A survey of somatic mutations in 41 genes in a cohort of T-cell lymphomas identifies frequent mutations in genes involved in epigenetic modification","volume":"27","author":"Fernandez-Pol","year":"2019","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.clml.2021.03.002_bib0033","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/PAS.0000000000000555","article-title":"Angioimmunoblastic T-cell lymphomas with the RHOA p.Gly17Val mutation have classic clinical and pathologic features","volume":"40","author":"Ondrejka","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2021.03.002_bib0034","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/PAS.0000000000000651","article-title":"Clinicopathologic analysis of angioimmunoblastic T-cell lymphoma with or without RHOA G17V mutation using formalin-fixed paraffin-embedded sections","volume":"40","author":"Nagao","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2021.03.002_bib0035","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.002_bib0036","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1182\/blood-2014-02-555946","article-title":"The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature","volume":"123","author":"Manso","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.002_bib0037","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ijc.10758","article-title":"Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4","volume":"103","author":"Lee","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2021.03.002_bib0038","doi-asserted-by":"crossref","first-page":"e28208","DOI":"10.4161\/sgtp.28208","article-title":"Rho-GTPases as key regulators of T lymphocyte biology","volume":"5","author":"Saoudi","year":"2014","journal-title":"Small GTPases"},{"key":"10.1016\/j.clml.2021.03.002_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2011.12.003","article-title":"Rho GTPases: masters of T lymphocyte migration and activation","volume":"142","author":"Rougerie","year":"2012","journal-title":"Immunol Lett"},{"key":"10.1016\/j.clml.2021.03.002_bib0040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/ng.2984","article-title":"Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma","volume":"46","author":"Kakiuchi","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2021.03.002_bib0041","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/gcc.22202","article-title":"Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols","volume":"53","author":"Rohde","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2021.03.002_bib0042","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/blood-2015-06-644948","article-title":"Variegated RHOA mutations in adult T-cell leukemia\/lymphoma","volume":"127","author":"Nagata","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.002_bib0043","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/pin.12981","article-title":"RHOA mutation in follicular T-cell lymphoma: clinicopathological analysis of 16 cases","volume":"70","author":"Miyoshi","year":"2020","journal-title":"Pathol Int"},{"key":"10.1016\/j.clml.2021.03.002_bib0044","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.002_bib0045","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.002_bib0046","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/path.5376","article-title":"Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell","volume":"250","author":"Yao","year":"2020","journal-title":"J Pathol"},{"key":"10.1016\/j.clml.2021.03.002_bib0047","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.002_bib0048","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00277-015-2332-0","article-title":"Double somatic mosaic mutations in TET2 and DNMT3A\u2013origin of peripheral T cell lymphoma in a case","volume":"94","author":"Nguyen","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.03.002_bib0049","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2021.03.002_bib0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2021.03.002_bib0051","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1126\/science.1170944","article-title":"Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha","volume":"324","author":"Zhao","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.clml.2021.03.002_bib0052","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00401-010-0790-y","article-title":"R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1alpha upregulation in adult glioma","volume":"121","author":"Williams","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.clml.2021.03.002_bib0053","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11060-011-0625-2","article-title":"IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients","volume":"105","author":"Metellus","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.clml.2021.03.002_bib0054","doi-asserted-by":"crossref","first-page":"16462","DOI":"10.18632\/oncotarget.24536","article-title":"IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme","volume":"9","author":"Polivka","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2021.03.002_bib0055","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/leu.2017.273","article-title":"Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma","volume":"32","author":"Fujisawa","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.03.002_bib0056","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/0008-5472.CAN-19-2787","article-title":"Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma","volume":"80","author":"Nguyen","year":"2020","journal-title":"Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502100104X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502100104X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:44Z","timestamp":1761871004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502100104X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S215226502100104X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.03.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma: A Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}